Home > Back to Publisher > Report Information

Global Biotech Market Analysis and Forecasts, 2008-2023

Visiongain
August 26, 2008
150 Pages - SKU: VSG2026719

Abstract Table of Contents Related Reports

Countries covered: Global

The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970’s. The leading biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other biotechnology companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market.

Over the period from 2008 to 2023, Visiongain expects the healthcare biotechnological market to continue its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development.

This brand new report - Global Biotech Market, 2008-2023- examines the healthcare biotech market critically, through comprehensive research and analysis. This report covers both the top ten therapy classes as well as the top ten leading pharmaceutical products in the biotech market in particular, as well as leading pipeline agents. Furthermore, Visiongain applied techniques such as their in-house financial forecasting technology, SWOT analyses, R&D pipeline analysis and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

You will not find this information available anywhere else.

Why you should buy this report:

In particular, our Global Biotech Market, 2008-2023 report concentrates on the following essential aspects of that market, including the competitive environment for original branded products and biogenerics:

Detailed analysis of the global biotech market, including an overall market sales forecast for 2008-2013, 2018 and 2023
Sales forecasts for leading products and therapeutic areas for 2008-2013, 2018 and 2023
Discussions of issues affecting the market segments, including SWOT analysis
Drivers and opportunities in the biotech industry
Restraints and threats facing the biotech industry
Discussion of the leading companies and their strategy in the context of the market
Pipeline developments and their implications for the future
Strategic alliances and licensing.

There are significant financial benefits from a company’s having a portfolio of biotech drugs, especially in this very uncertain period, when technological and commercial change is accelerating. This realisation has caused the major pharmaceutical companies to establish themselves in the biotech market. At least half of the top ten pharmaceutical companies now have leading biotech drugs. Thinning developmental pipelines in small molecule agents can, in part, explain big pharma's embracing of the biotech market, forcing them to buy biotech firms with promising drugs in development. This report provides valuable commercial information on this exciting industry that no healthcare company should ignore.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

1 Executive Summary: 1.1 Global Biotech Market Review: Entering a Crucial Period; 1.2 Aims, Scope and Format of the Report
2 Introduction to Biotechnology: 2.1 What is Biotechnology?; 2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around; 2.3 Biotechnologies Used and Their Applications to Pharma
3 The Leading Biotech Therapy Classes Market Forecast 2008-2013, 2018 & 2023: 3.1 The Top 10 Therapy Classes - Analysis & Forecasts; 3.2 Top 10 Therapy Classes: Summary of Forecasts
4 The Global Biotech Market 2008-2013, 2018 & 2023 - Top 10 Leading Products, Analysis and Forecasts: 4.1 The Global Biotech Market Showed Impressive Revenues in 2007; 4.2 The Top 10 Selling Biotech Drugs of 2007 Accounted for Half of Total Biotech Drug Sales; 4.3 The Top 5 Biotech Products of 2007; 4.4 Enbrel Currently Leads the World Biotech Market; 4.5 Aranesp Sales Outlook from 2008 Onwards; 4.6 Remicade Sales Outlook from 2008 Onwards; 4.7 MabThera/Rituxan Sales Outlook from 2008 Onwards; 4.8 Neulasta Sales Outlook from 2008 Onwards; 4.10 Herceptin Sales Outlook from 2008 Onwards; 4.11 Epogen Sales Outlook from 2008 Onwards; 4.12 Avastin Sales Outlook from 2008 Onwards; 4.13 Humira Sales Outlook from 2008 Onwards; 4.13.1 Humira (adalimumab); 4.14 Top 10 Leading Products Summary
5 SWOT Analysis 2008-2013: 5.1 SWOT Analysis of the Global Biotech Market; 5.2 Market Drivers; 5.3 Market Restraints; 5.4 The Biotech Market is Rapidly Expanding; 5.5 The Benefits of Biotechnological Products; 5.6 Biotechnology is an Important and Fast-Growing Part of Healthcare R&D; 5.7 Regulatory Issues; 5.8 Biotech Market Challenges; 5.9 Biotech's Major Challenges: Biogenerics and Budgetary Restraints; 5.10 Challenges and Issues for the Future in Healthcare Biotechnology
6 The Top 10 Leading Players in the Biotech Market: 6.1 Amgen: The Reign Continues With a Prominent Share of 2007 Market; 6.2 The Strong Partnership Flourishes between Roche and Genentech; 6.3 The Continuing Success of International Biopharmaceuticals Companies is Dependent upon Important Drivers and Restraints
7 Global Biotech Market by Region: 7.1 The World Biotech Market is Dominated by the US; 7.2 Japanese and European Biotech World Market Shares - How will these Develop?; 7.3 The US Biotech Market Will Retain World Dominance; 7.4 The European Biotech Market Will See Reduced Growth; 7.4.1 Biosimilars Approval Rises In the EU Market; 7.5 Biocon and Abraxis Launch Breast Cancer Drug in India
8 Venture Capital Investment in Healthcare Biotechnology: 8.1 What is Venture Capital Investment?; 8.2 What Do VC’s Offer?; 8.3 What Do Venture Capitalists Do?; 8.4 Who are Venture Capitalists?; 8.5 Why Do Biotech Companies Need VC Funding?
9 Biogenerics - Overview: 9.1 The Emergence of Biogenerics (Biosimilars); 9.2 Improved Technology Has Strengthened the Case for Biogenerics; 9.3 Bioequivalence Will Remain Difficult to Demonstrate; 9.4 Biotech Drugs are Expensive to Develop; 9.5 Regulators and Patients are Cautious over Safety; 9.6 The Next Generation of Biotech Drugs will Restrain Growth in Biogenerics; 9.7 Regulations are the Main Concern for Biogenerics; 9.8 The Key Question for Biogenerics - How Innovative Do You Need to Be?
10 Biotech Pipeline: 10.1 Technology Driving Biopharma Pipeline; 10.2 Biotech Targeting Chronic Illness; 10.3 Late-Stage Erythropoietins Pipeline; 10.4 Late Stage Oncology Pipeline; 10.5 Late-Stage Human Insulins Pipeline; 10.6 Late-Stage Arthritis Pipeline; 10.7 Late-Stage Interferons Pipeline; 10.8 Late-Stage Immunostims Pipeline; 10.9 Late-Stage Immunosuppressives Pipeline; 10.10 Late-Stage Growth Hormones Pipeline; 10.11 Late-Stage Blood Factors Pipeline; 10.12 Late-Stage Vaccines Pipeline; 10.13 The Future of Biotech R&D
11 Conclusions - Biotech Comes of Age: 11.1 The Global Biotech Market in 2007 - Summary; 11.2 The Top 5 Biotech Products of 2007 Had Impressive Sales Figures; 11.2.1 Top 10 Leading Products Rank - 2007 and 2013 Comparison; 11.3 Erythropoietins Class Currently Leads the Biotech Market - But Will it Last?; 11.3.1 Top 10 Therapy Classes Rank - 2007 and 2013 Comparison; 11.4 Can Amgen Remain at the Forefront of the Global Biotech Industry and Continue to be a Strong Competitor in the Global Pharmaceutical Market?; 11.5 Biotech Drugs Often Target Niche Markets
List of Tables: Table 2.1 Definitions of Selected Biopharmaceuticals; Table 2.2 Summary of Biotechnologies; Table 2.3 The Top 10 Global Biotech Companies, 2007; Table 2.4 The Top 10 Leading Biotech Products, 2007; Table 3.1 Revenues ($m) for the Top Ten Therapy Classes', 2008-2013, 2018 & 2023; Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for Top Ten Therapy Classes, 2007 & 2013; Table 3.3 Top 10 Therapy Classes Rank Comparison, 2007 and 2013; Table 4.1 Top 10 Leading Drugs Revenue ($m) Forecast 2008-2013, 2018 & 2023; Table 4.2 Top 10 Drugs 6-Year CAGR (%) and Market Share (%), 2007 & 2013; Table 4.3 Top 10 Products Market Share (%) Comparison 2007 & 2013; Table 4.4 Enbrel Revenues ($m) 2008-2013, 2018 & 2023; Table 4.5 Aranesp Revenues ($m) 2008-2013, 2018 & 2023; Table 4.6 Remicade Revenues ($m) 2008-2013, 2018 & 2023; Table 4.7 MabThera/Rituxan Revenues ($m) 2008-2013, 2018 & 2023; Table 4.8 Neulasta Revenues ($m) 2008-2013, 2018 & 2023; Table 4.9 Procrit/Erypo Revenues ($m) 2008-2013, 2018 & 2023; Table 4.10 Herceptin Revenues ($m) 2008-2013, 2018 & 2023; Table 4.11 Epogen Revenues ($m) 2008-2013, 2018 & 2023; Table 4.12 Avastin Revenues ($m) 2008-2013, 2018 & 2023; Table 4.13 Humira Revenues ($m) 2008-2013, 2018 & 2023; Table 4.14 Top 10 Products Rank Comparison, 2007 and 2013; Table 5.1 A SWOT Chart for the Biotech Market, 2008-2013; Table 6.1 Biotech Company Revenues ($m), Company Market Share (%) 2007; Table 7.1 Global Biotech Market Revenues ($m) Forecast 2008-2013, 2018 & 2023; Table 7.2 Global Market Share (%) and Revenue ($m) by Country/Region, 2007; Table 7.3 Global Market Share (%) by Country/Region Compared, 2007 and 2013; Table 7.4 Region/Country Revenue forecast ($m) 2008-2013, 2018 & 2023; Table 7.5 Competing Biosimilar Epoietin Launched in 2007-2008; Table 10.1 Late-Stage Erythropoietins Pipeline, 2008; Table 10.2 Late Stage Oncology Pipeline, 2008; Table 10.3 Late-Stage Human Insulin Pipeline, 2008; Table 10.4 Late-Stage Arthritis Pipeline, 2008; Table 10.5 Late-Stage Interferons Pipeline, 2008; Table 10.6 Late-Stage Immunostim Pipeline, 2008; Table 10.7 Late-Stage Immunosuppressive Pipeline, 2008; Table 10.8 Late-Stage Growth Hormone Pipeline, 2008; Table 10.9 Late-Stage Blood Factors Pipeline, 2008; Table 10.10 Late-Stage Vaccines Pipeline, 2008; Table 11.1 Global Biotech Market Revenues ($m) Forecast 2008-2013, 2018 & 2023; Table 11.2 Top 10 Products Rank Comparison, 2007 and 2013; Table 11.3 Top 10 Therapy Classes Rank Comparison, 2007 and 2013
List of Figures: Figure 2.1 Total Number of Biotechnology Patents Granted: 1992-2002; Figure 2.2 Number of New Biopharmaceutical FDA Approvals: 2000-2005; Figure 3.1 Top Ten Therapy Classes Revenue ($m) Comparison, 2007 & 2013; Figure 3.2 Top Ten Therapy Classes Market Share (%), 2007; Figure 3.3 Top Ten Therapy Classes Market Share (%), 2013; Figure 3.4 Erythropoietins Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.5 Oncology Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.6 Human Insulins Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.7 Autoimmune Agents Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.8 Interferons Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.9 Immunostim Agents Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.10 Immunosuppressive Agents Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.11 Growth Hormones Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.12 Blood Factors Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 3.13 Pure Vaccines Class Revenue ($m) Forecast 2008-2013, 2018 & 2023; Figure 4.1 Global Biotech Market Sales Breakdown ($m) 2008-2013, 2018 & 2023; Figure 4.2 Top 10 Drugs vs. the Rest of the Portfolio (%) Contribution of Revenues, 2007 & 2013; Figure 4.3 Top 10 Products Market Share (%) 2007; Figure 4.4 Top 10 Products Market Share (%) 2013; Figure 4.5 World Revenues ($m) for Enbrel 2008-2013, 2018 & 2023; Figure 4.6 World Revenues ($m) for Aranesp 2008-2013, 2018 & 2023; Figure 4.7 World Revenues ($m) for Remicade 2008-2013, 2018 & 2023; Figure 4.8 World Revenues ($m) for MabThera/Rituxan 2008-2013, 2018 & 2023; Figure 4.9 World Revenues ($m) for Neulasta 2008-2013, 2018 & 2023; Figure 4.10 World Revenues ($m) for Procrit/Erypo 2008-2013, 2018 & 2023; Figure 4.11 World Revenues ($m) for Herceptin 2008-2013, 2018 & 2023; Figure 4.12 World Revenues ($m) for Epogen 2008-2013, 2018 & 2023; Figure 4.13 World Revenues ($m) for Avastin 2008-2013, 2018 & 2023; Figure 4.14 World Revenues ($m) for Humira 2008-2013, 2018 & 2023; Figure 6.1 Company Revenues from Leading Biotech Drugs ($m), 2007; Figure 6.2 Top 10 Leading Biotech Companies Market Share (%) 2007; Figure 7.1 Global Market Share (%) by Region, 2007; Figure 7.2 Global Market Share (%) by Region, 2013

More Global Research & Development Reports

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition by Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, ...

Global Biotechnology by IBISWorld
Global Biotechnology Biotechnology is the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living ...

Global Protein Therapeutics Market Forecast to 2015 by RNCOS
Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most ...

Global Pharmaceuticals, Biotechnology & Life Sciences by MarketLine
Introduction Global Pharmaceuticals, Biotechnology & Life Sciences industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to ...

Biotechnology by Global Industry Analysts
The global outlook series on Biotechnology provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird’s ...

See all reports like this >>

Global Biotech Market Analysis and Forecasts, 2008-2023

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service